Cytori Therapeutics CYTX has been awarded a contract that may be
valued up to $106 million by the U.S. Department of Health and Human Service's
Biomedical Advanced Research and Development Authority (BARDA), if all
Contract Options are executed. The Contract is for preclinical and clinical
development of the Company's cell therapy for the treatment of thermal burns
combined with radiation injury. The aim is to evaluate and create a new
countermeasure for thermal burns which would be useful following a
mass-casualty event. Cytori's cell therapy is based on a patient's own
adipose-derived stem and regenerative cells (ADRCs) processed by the Company's
proprietary Celution® System technology.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in